The Antidepressant Effects of Hypoglycaemic Agents: New Insights from an Analysis of the FDA Adverse Event Reporting System (FAERS) Database

被引：0
|
作者：
Carnovale, C. [1 ]
Battini, V. [1 ]
Gringeri, M. [1 ]
Mosini, G. [1 ]
Guarnieri, G. [1 ]
Radice, S. [1 ]
Clementi, E. [1 ]
Manen, R. P. V. [2 ]
机构：
[1] Univ studi Milano, Dept Biomed & Clin Sci, Milan, Italy
[2] Oracle Hlth Sci Global Business Unit, Kattendijke, Netherlands
来源：
DRUG SAFETY | 2022年 / 45卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
P350
引用
收藏
页码：1285 / 1285
页数：1
相关论文
共 50 条
  • [21] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    [J]. BMC Pharmacology and Toxicology, 24
  • [22] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [23] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [24] Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023
    Lin, Jinger
    Chen, Xiangqi
    Luo, Min
    Zhuo, Qianwei
    Zhang, Haosong
    Chen, Nuo
    Zhuo, Yunqian
    Han, Yue
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] Melanoma associated with TNFa inhibitor agents in the FDA Adverse Event Reporting System (FAERS): Analysis of reported outcomes
    Nardone, Beatrice
    Bhattacharya, Tanya
    Bruins, Finola M.
    Hammel, Josh A.
    Haugh, Isabel M.
    West, Dennis P.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB209 - AB209
  • [26] Atezolizumab and severe cutaneous adverse reactions: Data mining of the FDA Adverse Event Reporting System (FAERS) database
    Pecere, A.
    Bisinella, G. C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1251 - S1251
  • [27] Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
    Li, Yun
    Li, Hang
    Xiang, Zhongyuan
    [J]. HELIYON, 2024, 10 (06)
  • [28] Carfiilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS)
    Buck, Benjamin
    Kellett, Eric
    Addison, Daniel
    Vallakati, Ajay
    [J]. JOURNAL OF THE SAUDI HEART ASSOCIATION, 2022, 34 (03) : 134 - 141
  • [29] Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
    Timbrook, Tristan T.
    McKay, Lydia
    Sutton, Jesse D.
    Spivak, Emily S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [30] The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Caruso, I.
    Di Gioia, L.
    Di Molfetta, S.
    Caporusso, M.
    Cignarelli, A.
    Sorice, G. P.
    Laviola, L.
    Giorgino, F.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024,
12345